Keyphrases
Colitis
46%
Cancer Patients
45%
Infliximab
44%
Corticosteroids
44%
Diarrhea
43%
30-day Mortality
39%
Gastroenteritis
39%
International multicenter Study
39%
Survivorship
39%
Endoscopic Features
39%
COVID-19 Inpatients
39%
Symptom Resolution
39%
Treatment Modalities
39%
Histopathological Features
39%
Immune-related
39%
Risk Impact
39%
Immune Checkpoint Inhibitors
39%
Impact of Cancer
39%
Risk Treatment
39%
Patients with Cancer
39%
Risk Factors
39%
Long COVID
39%
In Cancer
39%
Post-acute Sequelae of SARS-CoV-2 Infection
28%
COVID-19
28%
Inflammation
24%
Remdesivir
16%
COVID-19 Disease
16%
Acute COVID-19
16%
Overall Survival
12%
Independent Risk Factors
11%
Core Outcome Measures
11%
Low Oxygen
11%
Lymphopenia
11%
Myalgia
11%
COVID-19 Diagnosis
11%
Gastrointestinal Diseases
11%
MD Anderson Cancer Center
11%
Common Symptoms
11%
Sleep Disturbance
11%
National Cancer Institute
11%
National Institutes of Health
11%
Adverse Events
9%
Pathological Findings
9%
Endoscopic Findings
9%
Checkpoint Inhibitors
7%
Assiut
6%
Cassian
6%
Michael K
6%
Gastroenterology & Hepatology
6%
Medicine and Dentistry
COVID-19
100%
Colitis
86%
Malignant Neoplasm
83%
Diarrhea
82%
Immune Checkpoint Inhibitor
79%
Infliximab
66%
Severe Acute Respiratory Syndrome Coronavirus 2
61%
Cancer
44%
Infection
41%
Systematic Review
39%
Enterocolitis
39%
Cohort Analysis
39%
Pandemic
39%
Digestive System Surgery
39%
Postcovid Syndrome
39%
Immunity
39%
Overall Survival
29%
Sequela
22%
Immunosuppressive Treatment
22%
Diseases
17%
Perioperative Medicine
15%
Remdesivir
13%
Lymphocytopenia
13%
Odds Ratio
9%
Mortality Rate
9%
Myalgia
8%
Sleep Disorder
8%
Infection Rate
8%
Adverse Event
8%
Endoscopy
8%
Venous Ulcer
8%
Gastrointestinal Distress
8%
All Cause Mortality
8%
Clinical Trial
8%
Risk Stratification
7%
Meta-Analysis
7%
Prognostication
7%
Clinician
7%
Clinical Immunology
5%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
88%
Infliximab
61%
Colitis
46%
Diarrhea
43%
Enterocolitis
39%
Immune Checkpoint Inhibitor
39%
Overall Survival
29%
Infection
25%
Immunosuppressive Agent
22%
Diseases
19%
SARS Coronavirus
16%
Infection Rate
8%
Solid Malignant Neoplasm
8%
Clinical Trial
6%
Gastrointestinal Symptom
6%
Myalgia
6%
Sleep Disorder
6%